[
  {
    "ts": null,
    "headline": "Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks",
    "summary": "Steve Cress, head of Quant at Seeking Alpha, picks 3 dividend and 3 AI stocks.",
    "url": "https://finnhub.io/api/news?id=06ab5ad64e39605105592585c099c9d696af95fedaaf79e9c61d1e50580d3c16",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763912700,
      "headline": "Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks",
      "id": 137584779,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462286293/image_1462286293.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Steve Cress, head of Quant at Seeking Alpha, picks 3 dividend and 3 AI stocks.",
      "url": "https://finnhub.io/api/news?id=06ab5ad64e39605105592585c099c9d696af95fedaaf79e9c61d1e50580d3c16"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside",
    "summary": "Cidara Therapeutics Inc. (NASDAQ:CDTX) is the top stock in our list of the hottest SMID-cap stocks so far in 2025 with a 717% share price surge year-to-date. Following the acquisition announcement by Merck & Co. Inc. (NYSE:MRK), Guggenheim analyst Seamus Fernandez downgraded his rating on Cidara Therapeutics from Buy to Neutral on November 17, according to […]",
    "url": "https://finnhub.io/api/news?id=6258618b62d9e823e6deaa7cf3619d3dd3a801431f466f16bd8fc209c362a922",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763899318,
      "headline": "Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside",
      "id": 137586793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Cidara Therapeutics Inc. (NASDAQ:CDTX) is the top stock in our list of the hottest SMID-cap stocks so far in 2025 with a 717% share price surge year-to-date. Following the acquisition announcement by Merck & Co. Inc. (NYSE:MRK), Guggenheim analyst Seamus Fernandez downgraded his rating on Cidara Therapeutics from Buy to Neutral on November 17, according to […]",
      "url": "https://finnhub.io/api/news?id=6258618b62d9e823e6deaa7cf3619d3dd3a801431f466f16bd8fc209c362a922"
    }
  }
]